Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead's Biktarvy Set For EU Approval

Executive Summary

A combination therapy – Gilead Science’s Biktarvy – a hybrid medicine and a generic can look forward to EU approval after getting the OK from the EMA’s drug evaluation committee last week.

You may also be interested in...

Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up


Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy

Biktarvy's strength in battle against ViiV Healthcare's dolutegravir franchises is seen as a 'double-edged sword' for Gilead in HIV contest amid foreseen old drug 'cannibalization'.

April CHMP Meeting: Disappointment In Advance For AB Science, Gilead Hopeful On Biktarvy

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts